FDA Adverse Event Injury Summary report: N

PROMUS PREMIER

MDR report key: 8818472 · Received July 23, 2019

Report

Report Number
2134265-2019-08513
Event Type
Injury
Date Received
July 23, 2019
Date of Event
July 11, 2019
Report Date
February 19, 2020
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
NIQ
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 0

DEVICE IS A COMBINATION PRODUCT.

Description of Event or Problem · 0

PROMUS PREMIER CHINA REGISTRY. IT WAS REPORTED THAT THE SUBJECT EXPERIENCED UNSTABLE ANGINA PECTORIS. IN JUNE 2019, THE SUBJECT WAS DIAGNOSED WITH UNSTABLE ANGINA PECTORIS. THE TARGET LESION #1 WAS LOCATED IN THE MID RIGHT CORONARY ARTERY (RCA) TO DISTAL RCA WITH 100% STENOSIS AND WAS 46 MM LONG, WITH A REFERENCE VESSEL DIAMETER OF 3.5 MM. THE TARGET LESION WAS TREATED WITH PRE-DILATATION AND PLACEMENT OF 2.50 MM X 28 MM AND 3.50 MM X 24 MM PROMUS PRIEMIERE STENTS. FOLLOWING THIS INTERVENTION, POST DILATATION WAS PERFORMED. POST PROCEDURAL STENOSIS WAS REPORTED AS 0%. EIGHT DAYS LATER, THE SUBJECT WAS DISCHARGED. IN (B)(6) 2019, 38 DAYS POST INDEX PROCEDURE, THE PATIENT WAS DIAGNOSED WITH UNSTABLE ANGINA PECTORIS AND WAS HOSPITALIZED ON THE SAME DAY. NO OTHER ACTION WAS TAKEN TO TREAT THE EVENT. THE OUTCOME OF THE EVENT WAS CONSIDERED TO BE RECOVERING/RESOLVING. IT WAS FURTHER REPORTED THAT A PERCUTANEOUS CORONARY INTERVENTION WAS PERFORMED AT A NON TARGET VESSEL REVASCULARIZATION TO TREAT THE EVENT AND, THEREFORE, IS NO LONGER RELATED TO THE STUDY DEVICES.

Additional Manufacturer Narrative · 1

DEVICE IS A COMBINATION PRODUCT.

Description of Event or Problem · 1

(B)(4) CLINICAL STUDY. IT WAS REPORTED THAT PATIENT EXPERIENCED UNSTABLE ANGINA PECTORIS. IN (B)(6) 2019, THE SUBJECT WAS DIAGNOSED WITH UNSTABLE ANGINA PECTORIS. THE TARGET LESION #1 WAS LOCATED IN THE MID RIGHT CORONARY ARTERY (RCA) TO DISTAL RCA WITH 100% STENOSIS AND WAS 46 MM LONG, WITH A REFERENCE VESSEL DIAMETER OF 3.5 MM. THE TARGET LESION WAS TREATED WITH PRE-DILATATION AND PLACEMENT OF 2.50 MM X 28 MM AND 3.50 MM X 24 MM PROMUS PRIEMIERE STENTS. FOLLOWING THIS INTERVENTION, POST DILATATION WAS PERFORMED. POST PROCEDURAL STENOSIS WAS REPORTED AS 0%. EIGHT DAYS LATER, THE PATIENT WAS DISCHARGED. IN (B)(6) 2019, 38 DAYS POST INDEX PROCEDURE, THE PATIENT WAS DIAGNOSED WITH UNSTABLE ANGINA PECTORIS AND WAS HOSPITALIZED ON THE SAME DAY. NO OTHER ACTION WAS TAKEN TO TREAT THE EVENT. THE OUTCOME OF THE EVENT WAS CONSIDERED TO BE RECOVERING/RESOLVING.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
610284 PROMUS PREMIER STENT, CORONARY, DRUG-ELUTING NIQ BOSTON SCIENTIFIC CORPORATION 9552 0022732382

Patients

Seq Age Sex Outcome Treatment
1 43 YR Required Intervention